| December 1, 2026 |
BIIB |
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR) |
Trial Milestone |
Phase 3 |
| December 1, 2026 |
VNDA |
A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use |
Trial Milestone |
Phase 3 |
| December 1, 2026 |
TGTX |
A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders |
Trial Milestone |
Phase 1 |
| December 1, 2026 |
RNAC |
Descartes-08 for Patients With Systemic Lupus Erythematosus |
Trial Milestone |
Phase 2 |
| December 3, 2026 |
GSK |
A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults |
Trial Milestone |
Phase 1 |
| December 3, 2026 |
REGN |
A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body |
Trial Milestone |
Phase 2 |
| December 3, 2026 est. |
WVE |
Next quarterly earnings (projected) |
Earnings |
— |
| December 4, 2026 |
JNJ |
A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms |
Trial Milestone |
Phase 1 |
| December 4, 2026 |
REGN |
A First In Human (FIH) Study to Learn if Different Doses of ALN-ANG3 Are Safe and Well Tolerated in Healthy Adults |
Trial Milestone |
Phase 1 |
| December 6, 2026 est. |
BMRN |
Next quarterly earnings (projected) |
Earnings |
— |
| December 6, 2026 est. |
OCGN |
Next quarterly earnings (projected) |
Earnings |
— |
| December 8, 2026 |
NVS |
A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fraction |
Trial Milestone |
Phase 1 |
| December 8, 2026 |
JNJ |
A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer |
Trial Milestone |
Phase 1 |
| December 8, 2026 est. |
PCRX |
Next quarterly earnings (projected) |
Earnings |
— |
| December 9, 2026 |
INCY |
Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa |
Trial Milestone |
Phase 1 |
| December 9, 2026 est. |
EYPT |
Next quarterly earnings (projected) |
Earnings |
— |
| December 10, 2026 est. |
MRNA |
Propionic Acidemia (mRNA-3927) — Registrational Data |
Trial Readout |
Registrational |
| December 10, 2026 est. |
SMMT |
Next quarterly earnings (projected) |
Earnings |
— |
| December 10, 2026 est. |
CGEM |
Next quarterly earnings (projected) |
Earnings |
— |
| December 11, 2026 est. |
IRON |
Next quarterly earnings (projected) |
Earnings |
— |
| December 11, 2026 est. |
CERS |
Next quarterly earnings (projected) |
Earnings |
— |
| December 11, 2026 est. |
XNCR |
Next quarterly earnings (projected) |
Earnings |
— |
| December 12, 2026 est. |
ANRO |
Next quarterly earnings (projected) |
Earnings |
— |
| December 12, 2026 est. |
OTLK |
Next quarterly earnings (projected) |
Earnings |
— |
| December 13, 2026 est. |
REGN |
Next quarterly earnings (projected) |
Earnings |
— |
| December 13, 2026 |
NVO |
Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected) |
Trial Milestone |
Phase 1 |
| December 13, 2026 est. |
ALKS |
Next quarterly earnings (projected) |
Earnings |
— |
| December 14, 2026 |
GSK |
A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age |
Trial Milestone |
Phase 3 |
| December 14, 2026 |
AMGN |
Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab) |
Trial Milestone |
Phase 3 |
| December 14, 2026 est. |
OLMA |
Next quarterly earnings (projected) |
Earnings |
— |
| December 14, 2026 est. |
ATXI |
Next quarterly earnings (projected) |
Earnings |
— |
| December 15, 2026 |
JNJ |
A Study of JNJ-89862175 for Treatment of Advanced Solid Tumors |
Trial Milestone |
Phase 1 |
| December 15, 2026 |
ABBV |
A Study to Assess the Adverse Events and How Oral Emraclidine Moves Through the Body of Healthy Elderly Adult Participants |
Trial Milestone |
Phase 1 |
| December 15, 2026 |
ABBV |
Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab |
Trial Milestone |
Phase 2 |
| December 15, 2026 |
ABBV |
A Study to Evaluate the Safety and Pharmacokinetics of Multiple Doses Upadacitinib, Tofacitinib, and Baricitinib in Healthy Adult Volunteers |
Trial Milestone |
Phase 1 |
| December 15, 2026 |
ABBV |
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa |
Trial Milestone |
Phase 3 |
| December 15, 2026 |
ARGX |
A Study to Assess the Absolute Bioavailability and How Adimanebart SC Moves Through the Body in Healthy Adult Participants |
Trial Milestone |
Phase 1 |
| December 15, 2026 |
IONS |
A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE) |
Trial Milestone |
Phase 3 |
| December 15, 2026 |
VNDA |
Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder |
Trial Milestone |
Phase 3 |
| December 15, 2026 |
EXEL |
Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma |
Trial Milestone |
Phase 3 |
| December 15, 2026 |
AAPG |
Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL |
Trial Milestone |
Phase 2 |
| December 15, 2026 |
AXSM |
Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN) |
Trial Milestone |
Phase 3 |
| December 15, 2026 |
AXSM |
Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol |
Trial Milestone |
Phase 3 |
| December 15, 2026 |
ARWR |
Study of ARO-ATXN2 Injection in Adults With Spinocerebellar Ataxia Type 2 |
Trial Milestone |
Phase 1 |
| December 15, 2026 |
PRAX |
A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety |
Trial Milestone |
Phase 3 |
| December 15, 2026 |
PRAX |
A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of Relutrigine |
Trial Milestone |
Phase 3 |
| December 15, 2026 |
KPTI |
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma |
Trial Milestone |
Phase 2/Phase 3 |
| December 15, 2026 |
KPTI |
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) |
Trial Milestone |
Phase 2 |
| December 15, 2026 |
MDGL |
A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES) |
Trial Milestone |
Phase 3 |
| December 15, 2026 |
MANE |
Safety and Efficacy of VDPHL01 in Males With AGA |
Trial Milestone |
Phase 3 |
| December 15, 2026 |
EIKN |
A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC |
Trial Milestone |
Phase 2 |
| December 15, 2026 |
KARD |
Study of Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospitalization and a Concurrent Episode of Acute Severe Hypertension |
Trial Milestone |
Phase 2 |
| December 15, 2026 |
VIR |
A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide |
Trial Milestone |
Phase 3 |
| December 15, 2026 |
CORT |
Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome |
Trial Milestone |
Phase 2 |
| December 15, 2026 |
DNTH |
A Clinical Study to Evaluate DNTH103 in Adults With Multifocal Motor Neuropathy |
Trial Milestone |
Phase 2 |
| December 15, 2026 |
RCUS |
A Study to Investigate the Safety, Tolerability, and PK of AB102 in Healthy Participants |
Trial Milestone |
Phase 1 |
| December 15, 2026 |
TARA |
Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age |
Trial Milestone |
Phase 2 |
| December 15, 2026 |
DNLI |
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN) |
Trial Milestone |
Phase 1/Phase 2 |
| December 15, 2026 |
KRYS |
A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa |
Trial Milestone |
Phase 3 |
| December 15, 2026 |
KRYS |
A Study Assessing KB407 for the Treatment of Cystic Fibrosis |
Trial Milestone |
Phase 1 |
| December 15, 2026 |
KRYS |
A Study Comparing KB801 Verse Placebo in Patients With Stage 2 or 3 Neurotrophic Keratitis |
Trial Milestone |
Phase 1/Phase 2 |
| December 15, 2026 |
MDWD |
A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE) |
Trial Milestone |
Phase 3 |
| December 15, 2026 |
OCS |
A Clinical Study Evaluating Licaminlimab for Dry Eye Disease |
Trial Milestone |
Phase 2/Phase 3 |
| December 15, 2026 |
AVIR |
Study of AT-587 in Healthy Subjects |
Trial Milestone |
Phase 1 |
| December 15, 2026 |
AVIR |
C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV |
Trial Milestone |
Phase 3 |
| December 15, 2026 |
DCTH |
Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease |
Trial Milestone |
Phase 2 |
| December 15, 2026 |
UTHR |
A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension |
Trial Milestone |
Phase 3 |
| December 15, 2026 |
ABVX |
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease |
Trial Milestone |
Phase 2 |
| December 15, 2026 est. |
PHAT |
Next quarterly earnings (projected) |
Earnings |
— |
| December 15, 2026 |
BEAM |
A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL) |
Trial Milestone |
Phase 1/Phase 2 |
| December 15, 2026 |
ORIC |
ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC |
Trial Milestone |
Phase 1 |
| December 15, 2026 |
KURA |
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia |
Trial Milestone |
Phase 1 |
| December 15, 2026 |
PCRX |
ZILRETTA in Subjects With Shoulder Osteoarthritis |
Trial Milestone |
Phase 3 |
| December 15, 2026 |
ANRO |
Study of ALTO-300 in MDD |
Trial Milestone |
Phase 2 |
| December 15, 2026 |
GNLX |
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) |
Trial Milestone |
Phase 3 |
| December 15, 2026 |
LXEO |
Gene Therapy for ACM Due to a PKP2 Pathogenic Variant |
Trial Milestone |
Phase 1/Phase 2 |
| December 15, 2026 |
TRAW |
This is an Early-stage Clinical Trial to Determine a Safe and Effective Dose for Tivoxavir Marboxil in Patients With Mild to Moderate Influenza |
Trial Milestone |
Phase 2 |
| December 15, 2026 |
AVLN |
AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF |
Trial Milestone |
Phase 2 |
| December 15, 2026 |
OMER |
Long-Term Safety, Tolerability and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria |
Trial Milestone |
Phase 2 |
| December 15, 2026 |
PVCT |
Indigotindisulfonate Sodium Injection, USP as an Aid in the Determination of Ureteral Patency in Pediatric Patients |
Trial Milestone |
Phase 3 |
| December 15, 2026 |
DMAC |
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial) |
Trial Milestone |
Phase 2/Phase 3 |
| December 15, 2026 |
KYMR |
First-in-human Study of Orally Administered KT-579 in Healthy Adult Participants |
Trial Milestone |
Phase 1 |
| December 15, 2026 |
ALDX |
A Clinical Trial Evaluating Patients With Primary Vitreoretinal Lymphoma |
Trial Milestone |
Phase 3 |
| December 15, 2026 |
GOSS |
Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT) |
Trial Milestone |
Phase 3 |
| December 15, 2026 |
ACIU |
A Study Investigating the Safety, Absorption, Elimination, and the Effect on the Immune System of ACI-19764 in Healthy Participants and in Participants With Cardiovascular Risk Factors |
Trial Milestone |
Phase 1 |
| December 15, 2026 |
AKBA |
SAD and MAD Study of AKB-9090 in Healthy Adult Participants |
Trial Milestone |
Phase 1 |
| December 15, 2026 |
CERS |
A Recovery and Lifespan Study Using INTERCEPT Red Blood Cells Prepared Using the INTERCEPT Blood System for RBCs With AS-1 |
Trial Milestone |
Phase 2 |
| December 15, 2026 |
LTRN |
A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma |
Trial Milestone |
Phase 2 |
| December 15, 2026 |
ALZN |
A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Subjects With Bipolar I Disorder |
Trial Milestone |
Phase 1/Phase 2 |
| December 15, 2026 |
CGEM |
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus |
Trial Milestone |
Phase 1 |
| December 16, 2026 |
MRNA |
A Study to Investigate Safety and Tolerability of mRNA-0184 Administered Subcutaneously in Healthy Participants |
Trial Milestone |
Phase 1 |
| December 16, 2026 est. |
DYN |
Next quarterly earnings (projected) |
Earnings |
— |
| December 17, 2026 |
BMY |
A Study to Assess the Relative Bioavailability of BMS-986435 and Food Effect on the BMS-986435 in Healthy Adult Participants |
Trial Milestone |
Phase 1 |
| December 17, 2026 est. |
VCEL |
Next quarterly earnings (projected) |
Earnings |
— |
| December 17, 2026 |
SRRK |
A Single- and Multiple-Ascending Dose Study of SRK-439 in Healthy Adults |
Trial Milestone |
Phase 1 |
| December 18, 2026 est. |
DFTX |
Next quarterly earnings (projected) |
Earnings |
— |
| December 18, 2026 est. |
RYTM |
Next quarterly earnings (projected) |
Earnings |
— |
| December 18, 2026 est. |
NVCR |
Next quarterly earnings (projected) |
Earnings |
— |
| December 18, 2026 est. |
MBX |
Next quarterly earnings (projected) |
Earnings |
— |
| December 18, 2026 est. |
LRMR |
Next quarterly earnings (projected) |
Earnings |
— |
| December 20, 2026 est. |
RIGL |
Next quarterly earnings (projected) |
Earnings |
— |
| December 21, 2026 est. |
JAZZ |
Next quarterly earnings (projected) |
Earnings |
— |
| December 21, 2026 est. |
BCRX |
Next quarterly earnings (projected) |
Earnings |
— |
| December 22, 2026 est. |
ACAD |
Next quarterly earnings (projected) |
Earnings |
— |
| December 22, 2026 est. |
SNDX |
Next quarterly earnings (projected) |
Earnings |
— |
| December 22, 2026 est. |
DCTH |
Next quarterly earnings (projected) |
Earnings |
— |
| December 22, 2026 |
ENSC |
Single Dose Study, Pharmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat (PF614-MPAR-102) |
Trial Milestone |
Phase 1 |
| December 23, 2026 est. |
MIRM |
Next quarterly earnings (projected) |
Earnings |
— |
| December 23, 2026 est. |
SRPT |
Next quarterly earnings (projected) |
Earnings |
— |
| December 23, 2026 est. |
KYMR |
Next quarterly earnings (projected) |
Earnings |
— |
| December 23, 2026 est. |
TRDA |
Next quarterly earnings (projected) |
Earnings |
— |
| December 23, 2026 est. |
AKBA |
Next quarterly earnings (projected) |
Earnings |
— |
| December 26, 2026 |
INCY |
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa |
Trial Milestone |
Phase 3 |
| December 26, 2026 est. |
IONS |
Next quarterly earnings (projected) |
Earnings |
— |
| December 27, 2026 est. |
KNSA |
Next quarterly earnings (projected) |
Earnings |
— |
| December 28, 2026 |
GSK |
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study |
Trial Milestone |
Phase 2 |
| December 28, 2026 est. |
GKOS |
Next quarterly earnings (projected) |
Earnings |
— |
| December 29, 2026 |
REGN |
A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia |
Trial Milestone |
Phase 2 |
| December 29, 2026 |
ALNY |
A Study to Evaluate ALN-4285 in Adult Healthy Volunteers |
Trial Milestone |
Phase 1 |
| December 30, 2026 |
NVS |
Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment |
Trial Milestone |
Phase 3 |
| December 30, 2026 |
JNJ |
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms |
Trial Milestone |
Phase 3 |
| December 30, 2026 |
SVA |
Immunogenicity and Safety of Rabies Vaccine (Serum-free Vero Cell) in a Pre-exposure Prophylaxis Regimen |
Trial Milestone |
Phase 3 |
| December 30, 2026 |
QNRX |
Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome |
Trial Milestone |
Phase 2/Phase 3 |
| December 30, 2026 |
QNRX |
Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome |
Trial Milestone |
Phase 2/Phase 3 |
| December 30, 2026 |
SUPN |
BIS-001-ER for the Treatment of Adult Focal Impaired Awareness Seizures |
Trial Milestone |
Phase 1/Phase 2 |
| December 30, 2026 |
RNAC |
Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis |
Trial Milestone |
Phase 3 |
| December 30, 2026 |
SLS |
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML |
Trial Milestone |
Phase 1/Phase 2 |
| December 30, 2026 |
NTHI |
NEO100 and High-Grade Meningioma |
Trial Milestone |
Phase 2 |
| December 30, 2026 |
TCRX |
A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors |
Trial Milestone |
Phase 1 |
| December 31, 2026 |
GSK |
Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors |
Trial Milestone |
Phase 1 |
| December 31, 2026 |
JNJ |
A Long-term Extension Study of PCI-32765 (Ibrutinib) |
Trial Milestone |
Phase 3 |
| December 31, 2026 |
JNJ |
ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer |
Trial Milestone |
Phase 1 |
| December 31, 2026 |
AMGN |
Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC) |
Trial Milestone |
Phase 1 |
| December 31, 2026 |
NVO |
A Study Understanding How Much CDR132L Enters the Bloodstream After Injection Under the Skin Compared to Injection Into a Vein in Healthy Participants |
Trial Milestone |
Phase 1 |
| December 31, 2026 |
ARGX |
A Study to Assess the Safety of ARGX-124 in Healthy Volunteers |
Trial Milestone |
Phase 1 |
| December 31, 2026 |
ONC |
A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors |
Trial Milestone |
Phase 1 |
| December 31, 2026 |
ONC |
A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutinib |
Trial Milestone |
Phase 3 |
| December 31, 2026 |
AAPG |
Global Trial in APG2575 for Patients With CLL/SLL |
Trial Milestone |
Phase 3 |
| December 31, 2026 |
JAZZ |
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors |
Trial Milestone |
Phase 2 |
| December 31, 2026 |
RVMD |
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors |
Trial Milestone |
Phase 1 |
| December 31, 2026 |
INBS |
Evaluate the Safety, Tolerability of BAT6026 |
Trial Milestone |
Phase 1/Phase 2 |
| December 31, 2026 |
MRNA |
A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations |
Trial Milestone |
Phase 4 |
| December 31, 2026 |
INSM |
An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH) |
Trial Milestone |
Phase 2/Phase 3 |
| December 31, 2026 |
VIR |
A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection |
Trial Milestone |
Phase 3 |
| December 31, 2026 |
SRPT |
Study of SRP-1003 in Participants With Type 1 Myotonic Dystrophy |
Trial Milestone |
Phase 1/Phase 2 |
| December 31, 2026 |
VTRS |
A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus |
Trial Milestone |
Phase 3 |
| December 31, 2026 |
ANNX |
An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study) |
Trial Milestone |
Phase 3 |
| December 31, 2026 |
SUPN |
Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder |
Trial Milestone |
Phase 2 |
| December 31, 2026 |
MNOV |
MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia |
Trial Milestone |
Phase 2 |